2020
Cutaneous Vasculitis After Ustekinumab Induction in Crohn’s Disease
Chugh R, Proctor DD, Little A, Myung P, Cowper S, Imaeda S, Pashankar DS, Al-Bawardy B. Cutaneous Vasculitis After Ustekinumab Induction in Crohn’s Disease. Inflammatory Bowel Diseases 2020, 27: e30-e31. PMID: 33179735, DOI: 10.1093/ibd/izaa285.Peer-Reviewed Case Reports and Technical NotesHigh-throughput quantitative histology in systemic sclerosis skin disease using computer vision
Correia C, Mawe S, Lofgren S, Marangoni RG, Lee J, Saber R, Aren K, Cheng M, Teaw S, Hoffmann A, Goldberg I, Cowper SE, Khatri P, Hinchcliff M, Mahoney JM. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision. Arthritis Research & Therapy 2020, 22: 48. PMID: 32171325, PMCID: PMC7071594, DOI: 10.1186/s13075-020-2127-0.Peer-Reviewed Original ResearchConceptsSystemic sclerosisFibrosis scoreQuantitative image featuresBiopsy scorePrimary cohortOutcome measuresSecondary cohortDiagnostic scoreSkin severity scoreSSc clinical trialsRodnan skin scoreLogistic regression modelsControl biopsiesRegression modelsSkin scoreSeverity scoreClinical hallmarkClinical trialsForearm biopsiesSSc skinBiopsy sectionsIndependent cohortPatient basisSSc biopsiesCollagen deposition
2008
Nephrogenic Systemic Fibrosis: An Overview
Cowper SE. Nephrogenic Systemic Fibrosis: An Overview. Journal Of The American College Of Radiology 2008, 5: 23-28. PMID: 18180005, DOI: 10.1016/j.jacr.2007.08.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2007
Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders
Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis & Rheumatism 2007, 56: 3173-3175. PMID: 17907160, DOI: 10.1002/art.22926.Commentaries, Editorials and LettersNephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor
Moreno‐Romero J, Segura S, Mascaró JM, Cowper SE, Julià M, Poch E, Botey A, Herrero C. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. British Journal Of Dermatology 2007, 157: 783-787. PMID: 17627792, DOI: 10.1111/j.1365-2133.2007.08067.x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisDevelopment of NSFRenal insufficiency patientsOnset of symptomsNephrogenic fibrosing dermopathyPossible aetiological factorsMagnetic resonance angiographyRenal diseaseCase seriesAetiological factorsSystemic fibrosisResonance angiographyFibrotic conditionsPatientsParamagnetic contrast agentHistory of useDiseaseContrast agentsAngiographyFibrosisDermopathyEtiologyGadoliniumSymptomsGadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis
High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. Journal Of The American Academy Of Dermatology 2007, 56: 710-712. PMID: 17289213, DOI: 10.1016/j.jaad.2007.01.022.Peer-Reviewed Original ResearchGadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.Commentaries, Editorials and LettersNephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium
Cowper SE. Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium. Advances In Dermatology 2007, 23: 131-154. PMID: 18159899, DOI: 10.1016/j.yadr.2007.07.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2006
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. Journal Of The American Academy Of Dermatology 2006, 56: 21-26. PMID: 17097388, DOI: 10.1016/j.jaad.2006.10.047.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNSF patientsSystemic fibrosisGadolinium-containing contrast materialSubset of patientsSoft tissueNumber of patientsPilot investigationTissues of patientsGadolinium-based contrastGadolinium-containing contrast agentsParaffin-embedded specimenNegative controlRenal insufficiencyDevelopment of diseasePathophysiologic mechanismsUnknown etiologyEpidemiologic associationPatientsContrast materialTissue residence timeSingle histological sectionTissue specimensBlocks of tissueDetection of gadoliniumNephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)
Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion In Rheumatology 2006, 18: 614-617. PMID: 17053507, DOI: 10.1097/01.bor.0000245725.94887.8d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisNephrogenic fibrosing dermopathyRenal insufficiencyClinical awarenessSystemic diseaseClinical spectrumTreatment optionsFibrogenic factorsEffective therapyFatal disorderEnigmatic disorderClinical reportsCardinal featuresFibrosisSpecific causesDisordersPathogenesisFibrocytesFuture studiesCauseRheumatologistsPatientsEtiopathogenesisRegistryNephrogenic systemic fibrosis: An update
Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: An update. Current Rheumatology Reports 2006, 8: 151-157. PMID: 16569375, DOI: 10.1007/s11926-006-0056-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis—Setting the Record Straight
Cowper SE, Bucala R, Leboit PE. Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis—Setting the Record Straight. Seminars In Arthritis And Rheumatism 2006, 35: 208-210. PMID: 16461067, DOI: 10.1016/j.semarthrit.2005.09.005.Commentaries, Editorials and Letters
2005
Case 35-2004: nephrogenic fibrosing dermopathy.
Cowper S, Bucala R, LeBoit P. Case 35-2004: nephrogenic fibrosing dermopathy. New England Journal Of Medicine 2005, 352: 1723-4; author reply 1723-4. PMID: 15846862.Peer-Reviewed Original Research
2003
Nephrogenic fibrosing dermopathy: the first 6 years
Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Current Opinion In Rheumatology 2003, 15: 785-790. PMID: 14569211, DOI: 10.1097/00002281-200311000-00017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic fibrosing dermopathyRecent case reportsCase reportCutaneous fibrosing disorderYellow scleral plaquesDistinct clinical patternsDual immunohistochemical stainingAntiphospholipid antibodiesRenal insufficiencyClinical patternDual immunolabelingFibrosing disorderSystemic disordersClinical spectrumScleral plaquesDisease onsetEpidemiologic dataSpindle cellsImmunohistochemical stainingDisease triggersSkin conditionsDisease pathogenesisNormal skinRegistry projectDiagnostic tests
2001
Nephrogenic Fibrosing Dermopathy
Cowper S, Su L, Bhawan J, Robin H, LeBoit P. Nephrogenic Fibrosing Dermopathy. American Journal Of Dermatopathology 2001, 23: 383-393. PMID: 11801769, DOI: 10.1097/00000372-200110000-00001.Peer-Reviewed Original ResearchConceptsNephrogenic fibrosing dermopathyElastic fibersPositive dermal dendrocytesCollagen bundlesDifferent kidney diseasesThick collagen bundlesRenal transplantCutaneous changesDendritic cellsFibrosing disorderRenal diseaseSystemic findingsIndurated plaquesDermal mucinKidney diseaseSingle institutionDermal dendrocytesDialysis centersHistopathologic examinationHistopathologic findingsRenal dialysisEntire dermisSpindle cellsEarly lesionsRoutine microscopy
1999
p53, mdm-2, and p21 waf-1 in the Porokeratoses
Nelson C, Cowper S, Morgan M. p53, mdm-2, and p21 waf-1 in the Porokeratoses. American Journal Of Dermatopathology 1999, 21: 420. PMID: 10535569, DOI: 10.1097/00000372-199910000-00003.Peer-Reviewed Original ResearchConceptsTypes of porokeratosisCyclin-dependent kinase inhibitor p21P53 stainingP53 tumor suppressor gene productCornoid lamellaP21 expressionPorokeratosesCell cycle progressionMdm-2Waf-1Inhibitor p21Potential roleTumor suppressor gene productP53 tumor suppressor proteinP21 proteinSuppressor gene productCycle progressionMDM2Tumor suppressor proteinGene productsP53Cell cycle controlPrevious findingsP21Suppressor proteinExpression of p-27 (kip1) in Nevi and Melanomas
Morgan M, Cowper S. Expression of p-27 (kip1) in Nevi and Melanomas. American Journal Of Dermatopathology 1999, 21: 121-124. PMID: 10218670, DOI: 10.1097/00000372-199904000-00002.Peer-Reviewed Original ResearchConceptsExpression of p27Melanocytic lesionsSpitz neviDistribution of immunoreactivityP27 labeling indexMinority of casesCell cycle inhibitory proteinsChart reviewMalignant melanocytic lesionsClinical historyDiagnostic challengeBiologic behaviorHistopathologic criteriaLabeling indexCompound neviLogistic regressionHuman neoplasmsNeviNuclear stainingLesionsMelanomaP27Inhibitory proteinAccurate distinctionSkin